Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...
MedPage Today on MSN
Zeroing in on the disparities in multiple myeloma care, outcomes
Estimates based on the most recent data from the NCI's Surveillance, Epidemiology, and End Results (SEER) program show that ...
Teclistamab-cqyv plus subcutaneous daratumumab significantly improved OS and PFS in relapsed/refractory multiple myeloma compared to standard regimens, reducing death risk by 54%. The combination ...
The FDA has awarded its latest national priority voucher to Johnson & Johnson’s Tecvayli (teclistamab-cqyv) in combination with daratumumab for the treatment of relapsed or refractory multiple myeloma ...
Linvoseltamab-gcpt shows a 71% overall response rate and 52% complete response rate in heavily pretreated multiple myeloma patients. The drug's intravenous administration reduces hospitalization ...
Johnson & Johnson’s Tecvayli (teclistamab-cqyv), used in combination with daratumumab to treat relapsed or refractory multiple myeloma, has received FDA’s latest national priority voucher, becoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback